
FMC (FMC) Stock Forecast & Price Target
FMC (FMC) Analyst Ratings
Bulls say
FMC is well positioned for a fundamental recovery because its balanced crop portfolio, global reach, and acquisitions have made it one of the five largest patented crop protection companies, while its R&D pipeline is set to drive meaningful new-product revenue. The company plans to launch about 20 new diamide formulations between 2024 and 2033, with new active ingredients expected to rise to $300M-$400M in 2026 from $200M in 2025, supporting volume growth led by Brazil and EMEA and expanding margins. At the same time, management actions and asset sales should help stabilize leverage, with net debt/EBITDA moving to about 5.5x and over $1B in 2026 proceeds helping offset a difficult operating backdrop as farmer profitability improves.
Bears say
FMC is facing a fundamentally weak setup because Q3 adj. EBITDA of -$559M masked only $113M of underlying EBITDA, still below consensus, while abrupt channel destocking, softer demand, and generics-driven price pressure keep undermining volumes and net pricing. Management’s lower Q4 and FY26 guidance, including FY26 EBITDA of -$124M to -$104M and free cash flow of -$350M to -$150M, suggests earnings recovery will remain uneven despite the planned commercial reset and preliminary 2027/2028 EBITDA frameworks. Heavy leverage of 6.1x covenant net debt, a reduced equity base, and limited near-term visibility into consistent growth make the stock vulnerable until the company proves that its product pipeline and pricing actions can sustainably offset weak farm fundamentals.
This aggregate rating is based on analysts' research of FMC and is not a guaranteed prediction by Public.com or investment advice.
FMC (FMC) Analyst Forecast & Price Prediction
Start investing in FMC (FMC)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About FMC (FMC) Forecast
FMC (FMC) Analyst Forecast & Price Prediction
Start investing in FMC (FMC)
Order type
Buy in
Order amount
Est. shares
0 shares